If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...
Discover how scientists engineered goldenberry plants to grow 35% shorter than usual, making them suitable for large-scale ...
A one-year-old baby boy has received an incredible honour, for helping researchers get one step closer to finding treatment ...
AZoLifeSciences on MSN
Syntax Bio develops CRISPR technology to program stem cell gene activity
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...
A rare disease mom and scientist shares on the "First Opinion Podcast" how she serves as a translator between her two ...
8don MSN
Teens may have come up with a new way to detect, treat Lyme disease using CRISPR gene editing
To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...
Bispecific antibodies bring multiple tumor-cell-killing mechanisms into play simultaneously. When a T cell is activated and ...
7don MSN
Are university policies holding science back? Study shows how patenting boosts pure research
When UC Berkeley biochemist Jennifer Doudna first began studying how bacteria fight virus infections, she had no idea it ...
Cardiologist and Men's Health advisory board member Christopher Kelly, MD, says this treatment is "approaching magic" for ...
Researchers used CRISPR to change the number of chromosomes in Arabidopsis by fusing chromosome arms, reducing the genome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback